Canbex Therapeutics receives £1.75 million Translation Award from the Wellcome Trust
Canbex Therapeutics Ltd. announced today that it has received a Translation Award of up to 1.75 million ($2.8 million) from the Wellcome Trust to support development of a drug for the treatment of the debilitating muscle spasms associated with multiple sclerosis and potentially other disorders.
The award will facilitate further preclinical development of Canbex’s VSN series of compounds and the progression into clinical trials. It is anticipated that a Phase I trial of lead compound VSN16R could begin in December 2012.
Preclinical studies have shown that VSN16R treatment reduces muscle spasms in an animal model of MS spasticity, with a far lower burden of side effects than the decades-old compounds that are currently in clinical use. Even at high doses, animals treated with of VSN16R did not show the limpness and muscle flaccidity, know as the “rag doll effect”, that is a characteristic of existing compounds.
Current forms of treatment for spasticity are unsatisfactory, and a drug against spasticity that is well tolerated and effective could make a substantial difference to quality of life for MS patients and potentially many others.
Canbex has been developing its VSN series of compounds with the support of investors including Fast Forward LLC, a not for profit organization established by the National Multiple Sclerosis Society, USA, to accelerate the development of treatments for MS. “Fast Forward’s support has been a uniquely powerful endorsement of our efforts, one which has encouraged other funders and the MS community to engage with us,” Stephane Mery said.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Aseptika Granted United States Patent for Biomarkers for Respiratory Infection Onset
A new mechanism protects against cancer cell migration and neuron hyperexcitability
Lab901 and Biofortuna to collaborate on automated PCR Dx for HLA and Coeliac disease
Asterion Raises £355k Funding to Progress Novel Therapies for Hormone Related Diseases
Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase
Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer
Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness
